[
    [
        {
            "time": "2021-12-08",
            "original_text": "The FDA authorized the third antibody infusion therapy. Here’s why Vir and GSK say the U.S. still needs COVID-19 treatments",
            "features": {
                "keywords": [
                    "FDA",
                    "authorized",
                    "antibody",
                    "infusion",
                    "Vir",
                    "GSK",
                    "COVID-19",
                    "treatments"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "The FDA authorized the third antibody infusion therapy. Here’s why Vir and GSK say the U.S. still needs COVID-19 treatments",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-08",
            "original_text": "U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment",
            "features": {
                "keywords": [
                    "U.S.",
                    "stops",
                    "distributing",
                    "Lilly",
                    "COVID-19",
                    "antibody",
                    "Regeneron",
                    "treatment"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-08",
            "original_text": "Eli Lilly Receives DOJ Subpoena Related to Manufacturing Site",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "DOJ",
                    "Subpoena",
                    "Manufacturing",
                    "Site"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly Receives DOJ Subpoena Related to Manufacturing Site",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]